Skip to main content

Clinical trial OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors

Organ Multiple
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 1
Academic trial Non
Sponsor Onxeo
EudraCT Identifier 2017-000088-34
Inclusion criteria Any line/RECIST v1.1/Eligible for platinium salt chemotherapy
Last update